Erick Gamelin - May 14, 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Development Officer
Signature
/s/ Eric Devroe, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
May 14, 2025
Transactions value $
-$459
Form type
4
Date filed
5/16/2025, 04:18 PM
Previous filing
Mar 4, 2025
Next filing
Aug 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gamelin Erick Chief Development Officer C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Eric Devroe, Attorney-in-Fact 2025-05-16 0001950551

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability -$459 -403 -2.44% $1.14 16.1K May 14, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.